Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: Initially, 30 mg daily as a single dose or in divided doses for 4 weeks. May increase up to 60 mg daily for 4-6 weeks, if needed. Usual maintenance dose: 10-20 mg daily, or up to 40 mg daily.
Elderly: Half the normal maintenance dose.
Suy thận
Severe: Contraindicated.
Suy gan
Chống chỉ định
Known or suspected cerebrovascular disorders, CV disease, hypertension or history of headache, known or suspected phaeochromocytoma. Hepatic impairment (including history of liver disease or abnormal LFTs) and severe renal impairment. Concomitant use with or within 14 days of stopping SSRIs or other MAOIs; indirectly-acting sympathomimetic agents (e.g. amphetamines, metaraminol, fenfluramine, anorectic agents, ephedrine, phenylpropanolamine, dopamine, levodopa), pethidine, certain CNS depressants (including narcotics), antihypertensives, diuretic, antihistamines, sedatives or anaesthetic drugs, bupropion, buspirone, dextromethorphan, dibenzazepine derivatives, general anaesthesia used during elective surgery.
Thận trọng
Patient with diabetes, blood dyscrasias; at risk for seizure (e.g. history of seizure, head trauma, brain damage), history of suicide-related events, significant degree of suicidal ideation, history of substance abuse disorder, hyperthyroidism, schizophrenia, bipolar disorder, hypovolaemia. Restless or agitated patients; debilitated patients. Avoid abrupt withdrawal. Patients who will undergo surgery; discontinue treatment for at least 2 weeks prior to elective surgery. May mask anginal pain. Mild to moderate renal impairment. Elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Orthostatic hypotension, hepatic complications, jaundice, suicidal thoughts, self-harm, suicide-related events, increase or decrease in frequency of seizures; excessive excitement (in restless or agitated patients); shift to mania or hypomania (in patients with bipolar disorder).
Cardiac disorders: Palpitations.
Eye disorders: Blurred vision.
Gastrointestinal disorders: Dryness of mouth, nausea, vomiting, constipation.
General disorders and administration site conditions: Peripheral oedema, weakness, fatigue.
Nervous system disorders: Dizziness, drowsiness, headache, tremor, myoclonic jerks, paraesthesia.
Psychiatric disorders: Insomnia.
Renal and urinary disorders: Impotence, urinary frequency, urinary hesitancy.
Skin and subcutaneous tissue disorders: Diaphoresis.
Potentially Fatal: Hypertensive crisis.
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor renal function and liver function at baseline and as necessary; blood pressure, heart rate. Assess for changes in mood, signs and symptoms of suicidal ideation (particularly at the start of therapy and when doses are adjusted).
Quá liều
Symptoms: Ataxia, dizziness, irritability. For acute cases, hypotension or hypertension, convulsions, psychotic manifestation, tachycardia, respiratory depression, coma. Management: Supportive treatment. While keeping the airways protected, perform gastric lavage; provide emetics immediately after ingestion. For severe cases of hypotension, give plasma expanders. Administer pentolinium or pentolamine for hypertensive crisis and hydrocortisone for severe shock. Give diazepam to control convulsions or severe excitement. May perform dialysis in severe cases to eliminate the drug.
Tương tác
May potentiate the action of indirectly-acting sympathomimetic agents such as amphetamines, metaraminol, fenfluramine, or similar anorectic agents, ephedrine, or phenylpropanolamine, dopamine, levodopa; other CNS depressants (particularly barbiturates, phenothiazines), stimulants, local anaesthetics, ganglion-blocking drugs, other hypotensives (e.g. methyldopa, reserpine), diuretics, vasopressors, anticholinergic drugs, hypoglycaemic drugs. May enhance the side effect of morphine. May increase the hypertensive effect of bupropion and buspirone. Increased risk of brief psychotic episodes or bizarre behaviour with dextromethorphan. Increased risk of orthostatic hypotension with drugs that predispose to hypotension or bradycardia.
Potentially Fatal: Increased risk of serotonin syndrome with SSRIs or other MAOIs. Increased risk for central excitation, muscle rigidity, hyperpyrexia, circulatory collapse, respiratory depression and coma with pethidine.
Tương tác với thức ăn
May cause sudden and severe high blood pressure (e.g. hypertensive crisis or serotonin syndrome) with tyramine-containing foods such as mature cheeses (including processed cheeses), hydrolysed yeast or meat extracts, alcoholic beverages (especially heavy red wines), non-alcoholic beers, lagers, wines and other fermented food, pickles, hung, matured or otherwise subject to protein degradation before consumption; tyrosine, phenylalanine, tryptophan or caffeine-containing foods; avoid concurrent ingestion.
Tác dụng
Mechanism of Action: Isocarboxazid is a hydrazine derivative that inhibits the monoamine oxidase enzyme, therefore increasing the endogenous concentrations of epinephrine, norepinephrine, dopamine, and serotonin.
Absorption: Readily absorbed from the gastrointestinal tract. Time to peak plasma concentration: 3-5 hours.
Metabolism: Metabolised in the liver.
Excretion: Via urine (primarily as metabolites).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3759, Isocarboxazid. Accessed Apr. 27, 2023.

Bảo quản
Store below 25°C.
Phân loại MIMS
Thuốc chống trầm cảm
Phân loại ATC
N06AF01 - isocarboxazid ; Belongs to the class of non-selective monoamine oxidase inhibitors. Used in the management of depression.
Tài liệu tham khảo
Anon. Isocarboxazid. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/03/2023.

Buckingham R (ed). Isocarboxazid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/03/2023.

Joint Formulary Committee. Isocarboxazid. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 08/03/2023.

Marplan Tablet (Validus Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/03/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Isocarboxazid từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in